Aelis Farma

Bordeaux, France Founded: 2013 • Age: 13 yrs
Developer of small molecule drugs targeting CB1 receptor for CNS diseases

About Aelis Farma

Aelis Farma is a company based in Bordeaux (France) founded in 2013.. Aelis Farma has raised $14.04 million across 3 funding rounds from investors including Bpifrance, European Union and NACo. The company has 28 employees as of December 31, 2024. Aelis Farma offers products and services including AEF0117 and AEF0217. Aelis Farma operates in a competitive market with competitors including Indivior, Biotie, Ethypharm, Braeburn and Opiant Pharmaceuticals, among others.

  • Headquarter Bordeaux, France
  • Employees 28 as on 31 Dec, 2024
  • Stage Public
  • Sectors
    Healthcare
  • Email
    ***********
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Aelis Farma Sa
Operational Areas
Healthcare → Healthcare Products & Supplies
Key Metrics
  • Annual Revenue
    $2.78 M (USD)
    -70.42
    as on Dec 31, 2024
  • Net Profit
    $-7.75 M (USD)
    -46.83
    as on Dec 31, 2024
  • EBITDA
    $-10.75 M (USD)
    -7.86
    as on Dec 31, 2024
  • Total Equity Funding
    $14.04 M (USD)

    in 3 rounds

  • Latest Funding Round
    $4.05 M (USD), Grant

    Feb 01, 2021

  • Investors
    Bpifrance

    & 7 more

  • Employee Count
    28

    as on Dec 31, 2024

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

IPO & Listings of Aelis Farma

Aelis Farma is a publicly listed company on the EURONEXT with ticker symbol AELIS in France, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

Exchange: EURONEXT · Ticker: AELIS . Sector: Health technology · France

Products & Services of Aelis Farma

Aelis Farma offers a comprehensive portfolio of products and services, including AEF0117 and AEF0217. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

Targets cannabis use disorder through CB1 inhibition

Addresses cognitive deficits in conditions like Down syndrome

People of Aelis Farma
Headcount 1-10
Employee Profiles 8
Board Members and Advisors 1
Employee Profiles
People
Alexandra LE PEMP
CMC PROJECT MANAGER
People
Diego Grassi
Project Manager - Preclinical Development
People
Stéphanie Monlezun
COO
People
Pier Vincenzo Piazza
Director & CEO

Unlock access to complete

Board Members and Advisors
people
Anders Gersel Pedersen
Chairman

Unlock access to complete

Funding Insights of Aelis Farma

Aelis Farma has successfully raised a total of $14.04M across 3 strategic funding rounds. The most recent funding activity was a Grant round of $4.05 million completed in February 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 3
  • Last Round Grant — $4.1M
  • First Round

    (27 Mar 2014)

  • Investors Count 8
Date Amount Transaction Name Valuation Lead Investors Investors
Feb, 2021 Amount Grant - Aelis Farma Valuation

investors

Dec, 2019 Amount Seed - Aelis Farma Valuation Inserm Transfert , Bpifrance
Mar, 2014 Amount Seed - Aelis Farma Valuation

investors

Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Aelis Farma

Aelis Farma has secured backing from 8 investors, including institutional and venture fund investors. Prominent investors backing the company include Bpifrance, European Union and NACo. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
Investments are directed toward early-stage healthcare companies in France.
Founded Year Domain Location
-
Founded Year Domain Location
Early to Growth stage VC & PE firm funding
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Aelis Farma

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - Aelis Farma

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Aelis Farma Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Aelis Farma

Aelis Farma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Indivior, Biotie, Ethypharm, Braeburn and Opiant Pharmaceuticals, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Therapeutics for opioid addiction treatment are developed and commercialized.
domain founded_year HQ Location
Drugs for neurodegenerative and psychiatric disorders are developed by Biotie.
domain founded_year HQ Location
Therapies for pain and addiction treatment are developed.
domain founded_year HQ Location
Long-acting therapies for opioid addiction and chronic pain are developed.
domain founded_year HQ Location
Therapeutics for addictive and eating disorders are developed.
domain founded_year HQ Location
Therapies for substance use disorders are developed by Amygdala Neurosciences.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Aelis Farma

Frequently Asked Questions about Aelis Farma

When was Aelis Farma founded?

Aelis Farma was founded in 2013 and raised its 1st funding round 1 year after it was founded.

Where is Aelis Farma located?

Aelis Farma is headquartered in Bordeaux, France.

Who is the current CEO of Aelis Farma?

Pier Vincenzo Piazza is the current CEO of Aelis Farma.

Is Aelis Farma a funded company?

Aelis Farma is a funded company, having raised a total of $14.04M across 3 funding rounds to date. The company's 1st funding round was a Seed of $1.79M, raised on Mar 27, 2014.

How many employees does Aelis Farma have?

As of Dec 31, 2024, the latest employee count at Aelis Farma is 28.

What is the annual revenue of Aelis Farma?

Annual revenue of Aelis Farma is $2.78M as on Dec 31, 2024.

What does Aelis Farma do?

Aelis Farma was founded in 2013 in Bordeaux, France, as a biopharmaceutical company focused on CNS therapeutics. Small molecule inhibitors specific to CB1 receptor signaling are developed using a platform derived from the neurosteroid pregnenolone. Lead candidate AEF0117 addresses cannabis use disorder, while AEF0118 targets metabolic and fibrotic conditions. Operations emphasize preclinical and clinical advancement in the neurology sector.

Who are the top competitors of Aelis Farma?

Aelis Farma's top competitors include Indivior, Ethypharm and Amygdala Neurosciences.

What products or services does Aelis Farma offer?

Aelis Farma offers AEF0117 and AEF0217.

Is Aelis Farma publicly traded?

Yes, Aelis Farma is publicly traded on EURONEXT under the ticker symbol AELIS.

Who are Aelis Farma's investors?

Aelis Farma has 8 investors. Key investors include Bpifrance, European Union, NACo, Nouvelle-Aquitaine, and Inserm Transfert.

What is Aelis Farma's ticker symbol?

The ticker symbol of Aelis Farma is AELIS on EURONEXT.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available